Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
NRAS mutation
Cancer:
Myelodysplastic Syndrome
Drug:
Jakafi (ruxolitinib)
(
JAK2 inhibitor
,
JAK1 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Myelodysplastic…Subtype...CMML-2…Frequent mutations...TET2, SRSF2, ASXl1, RUNX1, NRAS, CBL…HMA ± ruxolitinib…
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login